Jw Pharmac - Asset Resilience Ratio
Jw Pharmac (001060) has an Asset Resilience Ratio of 3.65% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Jw Pharmac's Asset Resilience Ratio has changed over time. Check how strategically is Jw Pharmac's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Jw Pharmac's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Jw Pharmac (001060) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩22.11 Billion | 3.65% |
| Total Liquid Assets | ₩22.11 Billion | 3.65% |
Asset Resilience Insights
- Limited Liquidity: Jw Pharmac maintains only 3.65% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Jw Pharmac Industry Peers by Asset Resilience Ratio
Compare Jw Pharmac's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 48.48% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 15.57% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
Annual Asset Resilience Ratio for Jw Pharmac (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Jw Pharmac.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.65% | ₩22.11 Billion ≈ $14.98 Million |
₩605.27 Billion ≈ $410.18 Million |
-0.01pp |
| 2024-12-31 | 3.66% | ₩22.12 Billion ≈ $14.99 Million |
₩604.60 Billion ≈ $409.73 Million |
-8.48pp |
| 2023-12-31 | 12.14% | ₩78.29 Billion ≈ $53.05 Million |
₩645.04 Billion ≈ $437.13 Million |
-6.30pp |
| 2022-12-31 | 18.44% | ₩115.78 Billion ≈ $78.46 Million |
₩627.97 Billion ≈ $425.57 Million |
+13.34pp |
| 2021-12-31 | 5.10% | ₩32.30 Billion ≈ $21.89 Million |
₩633.05 Billion ≈ $429.01 Million |
-3.06pp |
| 2020-12-31 | 8.17% | ₩44.84 Billion ≈ $30.39 Million |
₩549.09 Billion ≈ $372.11 Million |
+8.16pp |
| 2016-12-31 | 0.00% | ₩20.00 Million ≈ $13.55K |
₩651.08 Billion ≈ $441.23 Million |
0.00pp |
| 2015-12-31 | 0.00% | ₩30.00 Million ≈ $20.33K |
₩613.48 Billion ≈ $415.75 Million |
-0.12pp |
| 2014-12-31 | 0.12% | ₩730.73 Million ≈ $495.20K |
₩594.12 Billion ≈ $402.63 Million |
-0.19pp |
| 2013-12-31 | 0.31% | ₩1.83 Billion ≈ $1.24 Million |
₩589.37 Billion ≈ $399.41 Million |
+0.05pp |
| 2012-12-31 | 0.26% | ₩1.58 Billion ≈ $1.07 Million |
₩603.15 Billion ≈ $408.74 Million |
+0.07pp |
| 2011-12-31 | 0.20% | ₩1.31 Billion ≈ $889.81K |
₩667.09 Billion ≈ $452.08 Million |
-3.66pp |
| 2006-12-31 | 3.86% | ₩19.89 Billion ≈ $13.48 Million |
₩515.85 Billion ≈ $349.58 Million |
-1.49pp |
| 2005-12-31 | 5.35% | ₩25.57 Billion ≈ $17.33 Million |
₩477.97 Billion ≈ $323.91 Million |
-0.45pp |
| 2004-12-31 | 5.80% | ₩26.55 Billion ≈ $17.99 Million |
₩457.56 Billion ≈ $310.08 Million |
-6.04pp |
| 2003-12-31 | 11.84% | ₩48.78 Billion ≈ $33.06 Million |
₩412.00 Billion ≈ $279.21 Million |
+5.83pp |
| 2002-12-31 | 6.02% | ₩23.19 Billion ≈ $15.72 Million |
₩385.60 Billion ≈ $261.32 Million |
-0.66pp |
| 2001-12-31 | 6.68% | ₩25.73 Billion ≈ $17.43 Million |
₩385.28 Billion ≈ $261.10 Million |
-2.16pp |
| 2000-12-31 | 8.84% | ₩35.14 Billion ≈ $23.81 Million |
₩397.46 Billion ≈ $269.35 Million |
-- |
About Jw Pharmac
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam steri… Read more